KPRX (Kiora Pharmaceuticals) Shiller PE Ratio: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KPRX Kiora Pharmaceuticals Inc KPRX
34 GF Score
Price $2.63
! 4 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kiora Pharmaceuticals  (NAS:KPRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Kiora Pharmaceuticals Shiller PE Ratio Related Terms


Kiora Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals Shiller PE Ratio Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kiora Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KPRX vs SNTI, PDSB, TOVX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Kiora Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Shiller PE Ratio falls into.


KPRX
34GF Score
Kiora Pharmaceuticals Inc KPRX
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kiora Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Kiora Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.3365/333.9520*333.9520
=-0.337

Current CPI (Jun. 2026) = 333.9520.

Kiora Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -1,944.000 241.428 -2,689.012
201612 -2,052.000 241.432 -2,838.354
201703 -1,512.000 243.801 -2,071.097
201706 -1,512.000 244.955 -2,061.340
201709 -1,296.000 246.819 -1,753.519
201712 -885.870 246.524 -1,200.038
201803 -744.498 249.554 -996.284
201806 -400.518 251.989 -530.792
201809 -390.582 252.439 -516.702
201812 -311.742 251.233 -414.384
201903 69.714 254.202 91.585
201906 -226.530 256.143 -295.343
201909 -413.752 256.759 -538.143
201912 -272.513 256.974 -354.146
202003 -155.322 258.115 -200.957
202006 -136.166 257.797 -176.391
202009 -158.872 260.280 -203.840
202012 -87.516 260.474 -112.204
202103 -98.374 264.877 -124.028
202106 -122.616 271.696 -150.712
202109 -4,082.868 274.310 -4,970.588
202112 -163.562 278.802 -195.917
202203 -98.280 287.504 -114.158
202206 -66.150 296.311 -74.553
202209 -54.298 296.808 -61.094
202212 -12.517 296.797 -14.084
202303 -9.025 301.836 -9.985
202306 -7.151 305.109 -7.827
202309 -7.971 307.789 -8.648
202312 -2.650 306.746 -2.885
202403 3.457 312.332 3.696
202406 -0.533 314.175 -0.566
202409 -0.810 315.301 -0.858
202412 -1.408 315.605 -1.489
202503 -0.520 319.799 -0.543
202506 -0.540 322.561 -0.559
202509 0.006 324.800 0.006
202512 -1.732 324.054 -1.785
202603 -0.579 330.213 -0.586
202606 -0.337 333.952 -0.337

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for KPRX

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.63
Price